Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
154 stopped studies mapped to Follicular Lymphoma and descendants · 86% state a reason
Over the 154 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05604417 | Zandelisib + Tazemetostat in R/R Follicular Lymphoma | Phase 1 / Phase 2 | withdrawn | Nov 3, 2022 | Jacob Soumerai, MD | Termination of Zandelisib clinical development globally | Other (stated, no rule matched) |
| NCT05934097 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | Phase 1 | withdrawn | Jul 6, 2023 | Fate Therapeutics | This study was withdrawn (Sponsor decision). | Sponsor / business decision |
| NCT04156828 | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory… | Phase 1 | terminated | Nov 8, 2019 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid… | Phase 1 / Phase 2 | terminated | May 12, 2015 | Asana BioSciences | Business decision | Sponsor / business decision |
| NCT05152459 | Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or… | Phase 1 / Phase 2 | withdrawn | Dec 9, 2021 | City of Hope Medical Center | Feasibility | Other (stated, no rule matched) |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Phase 1 | terminated | Sep 26, 2016 | MEI Pharma, Inc. | discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05176691 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | Phase 1 | withdrawn | Jan 4, 2022 | Hutchmed | HUTCHMED has decided to discontinue the HMPL 760 study. | Other (stated, no rule matched) |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT00096460 | Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent… | Phase 2 / Phase 3 | terminated | Nov 10, 2004 | Medical College of Wisconsin | lower than anticipated accrual | Enrollment / accrual |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | Phase 1 | terminated | Mar 4, 2021 | Samus Therapeutics, Inc. | Samus Therapeutics Company Closure | Sponsor / business decision |
| NCT04635683 | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory… | Phase 1 | withdrawn | Nov 19, 2020 | Yazeed Sawalha | Investigational Drug removed from the market | Other (stated, no rule matched) |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without…(UNITY-NHL) | Phase 2 / Phase 3 | terminated | Jun 8, 2016 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT04796922 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in… | Phase 3 | withdrawn | Mar 15, 2021 | Incyte Corporation | This study was withdrawn due to a business decision. | Sponsor / business decision |
| NCT04836832 | Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin… | Phase 1 | withdrawn | Apr 8, 2021 | Narendranath Epperla | PI decision | Other (stated, no rule matched) |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | Phase 1 | terminated | Apr 14, 2021 | Eden BioCell Ltd. | CAR-T manufacturing technology can not meet the dose requirement for clinical patients. | Drug supply |
| NCT00384111 | Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular… | Phase 3 | terminated | Oct 5, 2006 | Spectrum Pharmaceuticals, Inc | Study was terminated early as per the Sponsor's decision. | Sponsor / business decision |
| NCT04176913 | Study of LUCAR-20S in Patients With R/R NHL | Phase 1 | terminated | Nov 25, 2019 | The First Affiliated Hospital with Nanjing Medical University | Both the sponsors and collaborator are considering terminating the study | Other (stated, no rule matched) |
| NCT01510184 | Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly… | Phase 3 | terminated | Jan 13, 2012 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT03135262 | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants… | Phase 1 / Phase 2 | terminated | May 1, 2017 | Hoffmann-La Roche | Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2. | Sponsor / business decision |
| NCT00479167 | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With… | Phase 2 | terminated | May 28, 2007 | Rush University Medical Center | Lack of accrual and interest in study | Enrollment / accrual |
| NCT03685344 | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse… | Phase 1 | terminated | Sep 26, 2018 | ADC Therapeutics S.A. | In a limited number of patients, no additional activity was evident for the combination vs.… | Other (stated, no rule matched) |
| NCT01662102 | Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) | Phase 3 | terminated | Aug 10, 2012 | Spectrum Pharmaceuticals, Inc | Sponsor decision | Sponsor / business decision |
| NCT03585725 | A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and… | Early Phase 1 | terminated | Jul 13, 2018 | Weill Medical College of Cornell University | low accrual | Enrollment / accrual |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+… | Phase 1 / Phase 2 | terminated | Mar 5, 2013 | Northwestern University | Lack of funding | Funding |
| NCT01728207 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | Phase 1 | terminated | Nov 19, 2012 | Gilead Sciences | Study was stopped due to insufficient efficacy and very slow accrual | Efficacy / futility |
| NCT03178201 | TGR1202 in Relapsed and Refractory Follicular Lymphoma | Phase 2 | terminated | Jun 6, 2017 | Columbia University | PI left institution | Investigator |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT02576275 | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in… | Phase 3 | withdrawn | Oct 15, 2015 | SecuraBio | The scope of the program has been reduced to focus resources on studies which can potentially… | Other (stated, no rule matched) |
| NCT04342117 | Observational Trial of Real-World Treatment Utilization and Effectiveness of…(REAL) | — | terminated | Apr 10, 2020 | SecuraBio | Strategy Change | Sponsor / business decision |
| NCT01799889 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib… | Phase 2 | terminated | Feb 27, 2013 | Gilead Sciences | Sponsor's decision to discontinue development of entospletinib. | Sponsor / business decision |
| NCT04503538 | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | N/A | withdrawn | Aug 7, 2020 | Wake Forest University Health Sciences | Principal investigator decided not to pursue trial | Investigator |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | Phase 1 / Phase 2 | terminated | Jan 31, 2017 | Sunesis Pharmaceuticals | Phase 1b portion completed. Sponsor decided not to proceed with P2 portion of study. Vecabrutinib… | Sponsor / business decision |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and… | Phase 1 / Phase 2 | withdrawn | Oct 27, 2011 | Louisiana State University Health Sciences Center Shreveport | Investigator has relocated to MD Anderson | Investigator |
| NCT03436771 | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | — | terminated | Feb 19, 2018 | Juno Therapeutics, a Subsidiary of Celgene | Eligible subjects will be enrolled in Celgene's long-term follow-up protocol for subjects… | Enrollment / accrual |
| NCT00901927 | Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk… | Phase 2 | terminated | May 14, 2009 | M.D. Anderson Cancer Center | Study was closed early due to toxicity | Safety / toxicity |
| NCT01077518 | Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent…(A+B) | Phase 3 | terminated | Mar 1, 2010 | Novartis Pharmaceuticals | The study was terminated early as it did not meet the Primary efficacy objective after primary… | Efficacy / futility |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy,… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2018 | M.D. Anderson Cancer Center | Lack of Funding | Funding |
| NCT00022971 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | Phase 1 | terminated | Aug 20, 2001 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT02592876 | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for… | Phase 2 | terminated | Oct 30, 2015 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT02258529 | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and… | Phase 2 | terminated | Oct 7, 2014 | Gilead Sciences | not stated | Not stated |
| NCT01370694 | Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) | Phase 1 | terminated | Jun 10, 2011 | Merck Sharp & Dohme LLC | The study was terminated for business reasons. | Sponsor / business decision |
| NCT02855359 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in… | Phase 2 | terminated | Aug 4, 2016 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT02008006 | BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy…(BENEFIT) | Phase 2 | terminated | Dec 11, 2013 | Centre Leon Berard | Insufficient recruitment and unavailability of the treatment | Enrollment / accrual |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory… | Phase 1 | terminated | May 27, 2015 | Janssen Research & Development, LLC | Recent advances in the treatment of B cell malignancies resulting in new treatments being approved… | Other (stated, no rule matched) |
| NCT02702141 | A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma | Phase 1 | terminated | Mar 8, 2016 | Seagen Inc. | not stated | Not stated |
| NCT00012298 | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and… | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Trial completed prematurely. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 7, 2023source: clinicaltrials